Sie befinden sich hier
Inhalt
Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. At the Department of Pharmacology and Toxicology, we investigate the cellular and molecular mechanisms underlying cardiovascular disease.
Our research focuses on cardiac arrhythmias, heart failure, and vascular disease. We investigate the cellular and molecular mechanisms that drive the development and progression of these diseases, with particular emphasis on cellular calcium handling, metabolism, and intracellular signaling.
A special focus lies on atrial fibrillation. Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with increased morbidity and mortality, particularly due to embolic stroke and heart failure. Current approaches to restore normal sinus rhythm (antiarrhythmic drugs, AF ablation) have major limitations including dissatisfying efficacy and risk of life-threatening proarrhythmic events. Therefore, we aim to unravel novel molecular mechanisms contributing to AF initiation and maintenance. In particular, we employ modern experimental techniques including cellular electrophysiology and calcium imaging to investigate atrial myocytes and tissue samples from patients undergoing open heart surgery. In addition, we utilize advanced techniques in the generation of atrial engineered heart tissue (aEHM) and modern gene editing approaches (CRISPR/Cas9) in order to develop new experimental models of AF. These approaches will provide the molecular basis for novel and patient-tailored therapeutic strategies for AF.
Our research bridges multiple scales of cardiovascular biology, from the intact organ and cardiac tissue to individual cells, subcellular organelles, and ion channels. We combine human cells and tissue samples with advanced cellular, tissue, and animal models and integrate complementary experimental approaches to understand how molecular and cellular alterations translate into cardiovascular dysfunction.
A particular strength of our research is the close integration of basic and translational pharmacology. By linking mechanistic studies with human disease, we aim to identify new therapeutic targets and contribute to the development of more effective and individualized treatments for cardiovascular disorders.
Interested in our research or opportunities for collaboration? Please get in touch.
Prof. Dr. med. Niels Voigt
Campus Partners
Funding Partners
Quelle Bilder Abbildung:
1. https://academic.oup.com/eurheartj/article/47/13/1609/8249732
2. https://academic.oup.com/cardiovascres/article/119/16/2623/7263227
3. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066577
4. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.124.325658
5. https://www.nature.com/articles/s41596-026-01351-z
Kontextspalte
Department of Pharmacology and Toxicology
European Center for Angioscience (ECAS)
Medical Faculty Mannheim
Heidelberg University
Tridomus B
Ludolf-Krehl-Straße 7-11
68167 Mannheim
Director
Prof. Dr. Niels Voigt, FESC, FAHA
Phone +49 621 383-71750
(Secretariat)
niels.voigt@medma.uni-heidelberg.de